Afludol tablets 50mg, No. 20

• Prevention and treatment in adults and children: influenza A and B, ARVI, severe acute respiratory syndrome (including those complicated by bronchitis, pneumonia);

• secondary immunodeficiency states; complex therapy of chronic bronchitis, pneumonia and recurrent herpes infection.

• Prevention of postoperative infectious complications and normalization of the immune status.

• Complex therapy of acute intestinal infections of rotavirus etiology in children over 3 years old.

Afludol tablets should be taken orally, before meals.

Recommended single doses of the drug, depending on the patient's age:

adults and adolescents from 12 years old - 200 mg (2 tablets of 100 mg or 4 tablets of 50 mg);

children 6Ц12 years old - 100 mg (1 tablet of 100 mg or 2 tablets of 50 mg each);

children 3-6 years old - 50 mg (1 tablet 50 mg).

Recommended schemes for taking Afludol, depending on the indications:

nonspecific prevention of ARVI and influenza during an epidemic: 1 dose 2 times a week for 3 weeks;

non-specific prevention of acute respiratory viral infections and influenza after direct contact with the patient: 1 dose 1 time per day for 10-14 days;

treatment of influenza and acute respiratory viral infections: 1 dose 4 times a day (at intervals of 6 hours) for a course of 5 days;

complex therapy of pneumonia, chronic bronchitis, recurrent herpetic infection: 1 dose 4 times a day (at intervals of 6 hours) for 5-7 days, then - 1 dose 2 times a week for another 4 weeks;

prevention of postoperative infectious complications: 1 dose 2 days before surgery, then 1 dose 2 and 5 days after surgery.

Tablets, film-coated from white to white with a cream shade, round, biconvex, rough, at a break from white to white with a greenish-yellowish or cream shade.

1 tab.

umifenovir hydrochloride 50 mg

Excipients: lactose monohydrate - 0.0861 g, povidone K25 (medium molecular weight polyvinyl pyrrolidone) - 0.0032 g, crospovidone - 0.0047 g, colloidal silicon dioxide (aerosil) - 0.0045 g, magnesium stearate - 0.0015 g.

• Glucose-galactose malabsorption, lactose intolerance, lactase deficiency;

• children under 3 years old;

• hypersensitivity to any component of the drug.

pharmachologic effect

Antiviral agent. Specifically inhibits influenza A and B viruses, a coronavirus associated with severe acute respiratory syndrome. By the mechanism of antiviral action, it belongs to fusion inhibitors (fusion), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. Has a moderate immunomodulatory effect. It has interferon-inducing activity, stimulates humoral and cellular immune responses, phagocytic function of macrophages, increases the body's resistance to viral infections. Reduces the incidence of complications associated with a viral infection, as well as exacerbations of chronic bacterial diseases.

Therapeutic efficacy in viral infections is manifested in a decrease in the severity of general intoxication and clinical phenomena, a reduction in the duration of the disease, and a decrease in the risk of complications.

Refers to low-toxic compounds (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.

Pharmacokinetics

It is rapidly absorbed and distributed to organs and tissues. Cmax in blood plasma when taken at a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours.

It is metabolized in the liver. T1 / 2 is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount by the kidneys (0.12%). During the first day, 90% of the administered dose is excreted.

Side effect

Rarely: allergic reactions.

special instructions

It does not show central neurotropic activity and can be used in medical practice for prophylactic purposes in practically healthy individuals of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).